DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20852

Our STN: BL 103780/5062

JUN 30 2005

Serono, Inc.
Attention: Pamela Williamson Joyce, RAC
Vice President, Regulatory Affairs and Quality Assurance
One Technology Place
Rockland, MA 02370

Dear Ms. Williamson Joyce:

Your request to supplement your biologics license application for Interferon Beta-1a to revise the package insert to include information on a patient's ability to mount an appropriate immune response to the influenza vaccine has been approved.

This fulfills your commitment:

> "To conduct a study in 100 patients to evaluate the immunosuppressive effects of chronic Rebif treatment. The finalized protocol will be submitted to CBER by January 2003. Patient enrollment will be completed by December 2003, data collection completed by March 2004, and the final report with SAS datasets and applicable revised draft labeling will be submitted to CBER by June 2004,"

as stated in commitment #4 of the March 7, 2002 approval letter for STN # 103780/0.

As described in 21 CFR 601.70(e), we may publicly disclose information regarding these postmarketing studies on our Web site (**http://www.fda.gov/cder/pmc/default.htm**). Please refer to the April 2001 Draft Guidance for Industry: Reports on the Status of Postmarketing Studies – Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 (see **http://www.fda.gov/cber/gdlns/post040401.htm**) for further information.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels).

Please refer to http://www.fda.gov/cder biologics/default.htm for important information regarding therapeutic biological products, including the address for submissions Effective Oct 4, 2004, the new address for all submissions to this application is:

CDER Therapeutic Biological Products Document Room
Center for Drug Evaluation and Research
Food and Drug Administration

12229 Wilkins Avenue
Rockville, Maryland 20852

This information will be included in your biologics license application file.

Sincerely,

Marc K. Walton, M.D., Ph.D.
Director
Division of Therapeutic Biological Internal Medicine Products
Office of Drug Evaluation VI
Center for Drug Evaluation and Research

Cc: Package Insert (PI) 6.7.05

CONCURRENCE PAGE

Letter Type: LETTER: Approval (AP)
LETTER: Fulfillment of PMC (FPC)

Summary Text: Clinical Supplmt. - Labeling Only
REVIEW COMPLETION REQUIRED BY: RIS

SS Data Check:
- **Place copy of Approval Ltr. with original signature concurrence page in Archival package behind the "Approval Materials" Tab after LAR (Licensing Action Recommendation).**

RIS Data Check:
- **Verify short summary - Ltr. & Submission screen should match.**
- **Check Letter for PMCs (if PMCs - add "PMCs - Approved With" special characteristic code.)**
- **Perform Review Completion Process**
- **Milestone: Confirm Approved Status**

cc: HFD- 108/W. Bryan
HFD-108/E. Unger
HFD-108/M. Walton
HFD-109/K.Schneider
HFD-109/E.Dye
HFD-109/C.Michaloski
HFD-106/K. Weiss
HFD-106/G. Jones
HFM-110/RIMS/R. Eastep
HFD-400/ODS M. Dempsey
HFD-006/Exec sec P. Guinn
HFD-013/FOI D.Taub
HFD-013/FOI H. Brubaker
HFD-240/OTCOM/ B. Poole
HFD-230/OTCOM/CDER WebMaster
HFD-001/B. Duvall-Miller (if PMC commitments)
HFD-42/DDMAC/M. Kiester
HFD-410/ODS/DSRCS/ Karen Young
HFM-570 C. Lee (if clinical PMC commitments)
HFD-328/TFRB Blue File/Mike Smedley
HFD-410/CDER Medwatch Safety Labeling HFD-430/ODS/DDRE (hard copy)
DRMP BLA file (hard copy)

History: Michaloski: 6.6.05; 6.9.05

File Name: (S:Michaloski\letters\103780.5062Fluvacc.Supplement.doc)

Office	Name/Signature	Date
DRMP	C Michaloski	6-9-05
DRMP	Schneider	6-9-05
DRMP	[illegible] Dye	6-9-05
OTBTMP	[illegible]	6/30/05
DRMP	Kelly Cavenaugh	7/5/05